Source: Journal of Clinical Oncology. Unidade: FM
Subjects: NEOPLASIAS COLORRETAIS, ANTINEOPLÁSICOS (USO TERAPÊUTICO), BIOMARCADORES, METÁSTASE NEOPLÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KOPETZ, Scott et al. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. Journal of Clinical Oncology, v. 28, n. 3, p. 453-459, 2010Tradução . . Disponível em: https://doi.org/10.1200/JCO.2009.24.8252. Acesso em: 26 set. 2024.APA
Kopetz, S., Hoff, P. M., Morris, J. S., Wolff, R. A., Eng, C., Glover, K. Y., et al. (2010). Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. Journal of Clinical Oncology, 28( 3), 453-459. doi:10.1200/JCO.2009.24.8252NLM
Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance [Internet]. Journal of Clinical Oncology. 2010 ; 28( 3): 453-459.[citado 2024 set. 26 ] Available from: https://doi.org/10.1200/JCO.2009.24.8252Vancouver
Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance [Internet]. Journal of Clinical Oncology. 2010 ; 28( 3): 453-459.[citado 2024 set. 26 ] Available from: https://doi.org/10.1200/JCO.2009.24.8252